Combined Ribociclib and NU7026 Administration Enhances Radio-sensitivity by Inhibiting DNA Repair in Prostate Cancer

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2024 Dec 24

PMID 39718616

Authors

Jinbo Sun

Yong Wang

Shanjin Ma

Wei Zhang

Longfei Yang

Bo Zhang

Qisheng Tang

Affiliations

Soon will be listed here.

Abstract

Radiosensitivity is critical for clinical outcomes and overall survival of prostate cancer patients treated with irradiation. Ribociclib and NU7026 have been reported as radiosensitizers in cancer cells, but which are inadequately understood in prostate cancer cells. The present study was performed to investigate the effects of ribociclib, NU7026, and their combination on the radiosensitivity of prostate cancer cells. Optimal combined concentrations of ribociclib and NU7026 with X-irradiation were selected. Flow cytometry, CCK-8 assays, soft agar colony formation, and γH2AX foci formation assays were performed to assess the cell cycle distribution, cell viability, cell proliferation, and DNA damage, respectively. Finally, the expression of proteins related to the cell cycle, DNA repair, and cell death was evaluated by western blot analysis. Ribociclib arrested prostate cell cycle in the G0/G1 phase. Compared with the control, X-irradiation combined with ribociclib or NU7026 significantly decreased cell proliferation, reduced colony formation, and enhanced γH2AX foci formation in PC3 and DU145 cells. Moreover, the protein expression levels of CDK4, p-Rb, cyclin D1, rad51, and DNA-PKcs were significantly decreased, whereas that of Bax was significantly increased.The combination of ribociclib and NU7026 may be a potential strategy for prostate cancer therapy by promoting radiosensitivity.

References

Adams B, Hawkins A, Povirk L, Valerie K . ATM-independent, high-fidelity nonhomologous end joining predominates in human embryonic stem cells. Aging (Albany NY). 2010; 2(9):582-96. PMC: 2984607. DOI: 10.18632/aging.100197. View

Brighi N, Conteduca V, Lolli C, Gurioli G, Schepisi G, Palleschi M . The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. Crit Rev Oncol Hematol. 2020; 157:103199. DOI: 10.1016/j.critrevonc.2020.103199. View

Cojoc M, Peitzsch C, Kurth I, Trautmann F, Kunz-Schughart L, Telegeev G . Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. Cancer Res. 2015; 75(7):1482-94. DOI: 10.1158/0008-5472.CAN-14-1924. View

Daido S, Yamamoto A, Fujiwara K, Sawaya R, Kondo S, Kondo Y . Inhibition of the DNA-dependent protein kinase catalytic subunit radiosensitizes malignant glioma cells by inducing autophagy. Cancer Res. 2005; 65(10):4368-75. DOI: 10.1158/0008-5472.CAN-04-4202. View

Edessa D, Sisay M . Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib. Breast Cancer (Dove Med Press). 2017; 9:567-579. PMC: 5726365. DOI: 10.2147/BCTT.S150540. View

Gravel S, Chapman J, Magill C, Jackson S . DNA helicases Sgs1 and BLM promote DNA double-strand break resection. Genes Dev. 2008; 22(20):2767-72. PMC: 2569880. DOI: 10.1101/gad.503108. View

Hartwell L . Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell. 1992; 71(4):543-6. DOI: 10.1016/0092-8674(92)90586-2. View

Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S . Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016; 375(18):1738-1748. DOI: 10.1056/NEJMoa1609709. View

Infante J, Cassier P, Gerecitano J, Witteveen P, Chugh R, Ribrag V . A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res. 2016; 22(23):5696-5705. PMC: 5621377. DOI: 10.1158/1078-0432.CCR-16-1248. View

10.

Jette N, Lees-Miller S . The DNA-dependent protein kinase: A multifunctional protein kinase with roles in DNA double strand break repair and mitosis. Prog Biophys Mol Biol. 2015; 117(2-3):194-205. PMC: 4502593. DOI: 10.1016/j.pbiomolbio.2014.12.003. View

11.

Kuerbitz S, Plunkett B, Walsh W, Kastan M . Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A. 1992; 89(16):7491-5. PMC: 49736. DOI: 10.1073/pnas.89.16.7491. View

12.

Kwapisz D . Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. Breast Cancer Res Treat. 2017; 166(1):41-54. DOI: 10.1007/s10549-017-4385-3. View

13.

Lee H, Lee W, Kang C, Ku C, Cho Y, Lee E . A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer. Cancer Lett. 2018; 417:131-140. DOI: 10.1016/j.canlet.2017.12.037. View

14.

Li Y, Li H, Peng W, He X, Huang M, Qiu D . DNA-dependent protein kinase catalytic subunit inhibitor reverses acquired radioresistance in lung adenocarcinoma by suppressing DNA repair. Mol Med Rep. 2015; 12(1):1328-34. DOI: 10.3892/mmr.2015.3505. View

15.

Li X, Seebacher N, Garbutt C, Ma H, Gao P, Xiao T . Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma. Cell Death Dis. 2018; 9(5):446. PMC: 5906661. DOI: 10.1038/s41419-018-0474-4. View

16.

Lin Y, Nagasawa H, Little J, Kato T, Shih H, Xie X . Differential radiosensitivity phenotypes of DNA-PKcs mutations affecting NHEJ and HRR systems following irradiation with gamma-rays or very low fluences of alpha particles. PLoS One. 2014; 9(4):e93579. PMC: 3979685. DOI: 10.1371/journal.pone.0093579. View

17.

Liu Y, Majumder S, McCall W, Sartor C, Mohler J, Gregory C . Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res. 2005; 65(8):3404-9. DOI: 10.1158/0008-5472.CAN-04-4292. View

18.

Ma H, Takahashi A, Yoshida Y, Adachi A, Kanai T, Ohno T . Combining carbon ion irradiation and non-homologous end-joining repair inhibitor NU7026 efficiently kills cancer cells. Radiat Oncol. 2015; 10:225. PMC: 4638098. DOI: 10.1186/s13014-015-0536-z. View

19.

Marampon F, Gravina G, Ju X, Vetuschi A, Sferra R, Casimiro M . Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage. Oncotarget. 2015; 7(5):5383-400. PMC: 4868693. DOI: 10.18632/oncotarget.6579. View

20.

Marechal A, Zou L . DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. 2013; 5(9). PMC: 3753707. DOI: 10.1101/cshperspect.a012716. View